The exact role of triglycerides in heart ailment has been very tough to decide. To help untangle the knotty difficulty two investigation groups studied huge populations and recognized uncommon variations in a gene (APOC3) that encodes for apolipoprotein C3, which is acknowledged to increase triglyceride ranges.
In the first paper, published in the New England Journal of Medication, an NHLBI working group sequenced the genes of three,734 individuals and identified a number of uncommon loss-of-function variants of APOC3. As expected, men and women with the variants had drastically reduced triglyceride levels. The researchers then analyzed data from far more than 110,000 participants in 14 studies and observed that folks with the identical loss-of-perform mutations had a forty% reduce threat for coronary heart illness.
The results, create the authors, “show that reduction of APOC3 perform confers protection towards clinical coronary heart ailment,” even though they have been unable to recognize a primary mechanism linking APOC3 to heart condition.
In the 2nd paper, also published in the New England Journal of Medication, researchers used information from a lot more than 75,000 participants in two big Danish potential scientific studies to discover the position of APOC3. Men and women with APOC3 loss-of-perform mutations had triglyceride amounts decreased by 44%, with corresponding risk reductions of 41% for ischemic vascular ailment and 36% for ischemic heart disease.
Large Hope or Massive Hype?
The two research have acquired a great deal of attention in the media, which includes, most notably, fantastic stories with lots of information and standpoint by Gina Kolata on the front webpage of the New York Times and Matt Herper in Forbes. Both stories supply lots of background on these scientific studies and current a wide assortment of opinions about their significance. In standard, although, they recommend that triglycerides and HDL are prepared to trade roles: triglycerides are now prepared for prime time as HDL fades into the background.
Herper writes that the two scientific studies flip “triglycerides from an ignored supporting character into a key villain.” Kolata interviews Robert Hegele, who tells her that the scientific studies “provide ‘a extremely, very powerful type of evidence’… that triglycerides are in truth a cause of heart attacks.”
But a close examination of the NEJM papers suggests that it could be extremely difficult to link the result of APOC3 to its specific influence on triglycerides. In each scientific studies men and women with the reduction-of-perform mutations had drastically lowered triglycerides, but they also had significantly raised HDL amounts. LDL levels have been lowered as well. So it may possibly be challenging to figure out specifically what APOC3 is carrying out, and it is most likely as well soon to dethrone HDL and elevate triglycerides. We just do not know ample at this point.
The authors of the two NEJM papers publish that their findings suggest that APOC3 may possibly make for an eye-catching drug target. The two Kolata and Herper get up this suggestion and note that ISIS Pharmaceuticals has an anti-sense drug that targets APOC3 under advancement. Undoubtedly this is a promising new area, but it can not be emphasized strongly enough that this is nonetheless really early things. Here’s a warning I acquired from one top cardiologist. This research, he mentioned, “has definitely no implications for clinical practice. It may 1 day be seen as a pivotal examine that led to the development of exceptional drugs, but that is far away. I hope individuals really don’t go through it and consider that it has relevance to their recent choices about therapy.”
Big Genetic Research Might Help Unravel The Triglyceride Difficulty
Hiç yorum yok:
Yorum Gönder